

**Disclosure of interest** The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2016.01.646>

#### EW532

### Serum hormone levels and cognitive functioning in male schizophrenia patients

K. Krysta\*, A. Bratek, A. Koźmin-Burzyńska, I. Krupka-Matuszczyk  
Medical university of Silesia, department of psychiatry and psychotherapy, Katowice, Poland

\* Corresponding author.

**Background** Hormones deregulation is a common feature in schizophrenia. Among the hormones that gained increased interest are sex hormones, thyroid hormones and prolactin. However, the question whether there is an impact of the hormonal disturbances on cognitive functioning of schizophrenia patients is rarely addressed.

**Objective** To assess the relationship between serum levels of hormones and cognitive abilities in male schizophrenic patients.

**Subjects and methods** In the index group, there were 15 schizophrenia male patients, mean age 36. The control group was formed by 15 healthy volunteers, mean age 36. In the two groups, serum hormones levels were measured and neuropsychological tests were performed. Analysed hormones included thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, testosterone, progesterone and prolactin. Cognitive abilities were measured with the following tests: Trail Making Test (TMT) Part A and B, Semantic Category Fluency (SCF), Initial Letter Fluency (ILF) and Stroop Task Part 1 and 2.

**Results** The levels of FSH, LH and testosterone were lower in the index group than in the control group (3.01 mIU/mL vs 5.90 mIU/mL; 3.83 mIU/mL vs 5.28 mIU/mL; 2.76 ng/mL vs 4.69 ng/mL; accordingly) while the level of prolactin was higher in the index group (620 uIU/mL vs 118 uIU/mL). Patients performed worse than controls in all neuropsychological tests. The differences in scores of TMT Part B, ILF and Stroop Task Part 2 were found to be statistically significant.

**Conclusions** There was no significant relationship between serum level of analysed hormones and performance on cognitive tasks.

**Disclosure of interest** The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2016.01.650>

#### EW533

### Reaction time, processing speed and sustained attention in patients with schizophrenia: Impact on functioning

A. Orozco<sup>1</sup>, M. Vicens<sup>1</sup>, A. Ruiz<sup>1</sup>, A. Brañas<sup>1</sup>, G. Lahera<sup>2,\*</sup>

<sup>1</sup> Príncipe de Asturias university hospital, psychiatry, Alcalá-Madrid, Spain

<sup>2</sup> University of Alcalá- IRyCIS- CIBERSAM, medicine and medical specialties, Madrid, Spain

\* Corresponding author.

**Introduction** Some studies have related processing speed with functionality. A more discriminative analysis of different components of this neuropsychological construct is needed.

**Objectives/Aims** To measure the performance of a group of patients with schizophrenia in reaction time, processing velocity and sustained attention. To compare the impact on functioning of these three measures.

**Methods** Ninety-eight outpatients between 18 and 65 years diagnosed with schizophrenia, based on the DSM-V, with a 3-

month period of clinical stability, were recruited. Sociodemographic and clinical data were collected: PANSS scale, Akathisia Simpson-Angus Brief Scale, State-Trait Anxiety Inventory (STAI) and Global Functioning Scale (GAF). The following variables were measured: reaction time (SUPERLAB PRO), processing speed (TMT-A, subtest of symbol coding BACS, verbal fluency) and sustained attention (Continuous Performance Test).

**Results** Functionality of patients was correlated to Elective Reaction Time (the subject must react to different types of stimuli and to choose between several possible answers) [ $P = -0.205$ ;  $P = 0.047$ ], but NOT with Simple Reaction Time [ $P = 0.109$ ;  $P = 0.293$ ]. Functionality was significantly correlated to Symbols Coding ( $P = 0.328$ ;  $P = 0.001$ ), and a trend was observed regarding semantic fluency ( $P = 0.190$ ;  $P = 0.06$ ) and the TMT-A ( $P = -0.179$ ;  $P = 0.08$ ). In CPT, Correct Detection was correlated with GAF score ( $P = 0.380$ ;  $P = 0.000$ ) but not omission errors. The model of lineal regression shows a differential impact of every measure in global functioning.

**Conclusions** Reaction time, processing speed and sustained attention are different variables and each of them have impact on functioning in schizophrenia.

**Disclosure of interest** The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2016.01.651>

#### EW534

### Monotherapy treatment with cariprazine for the treatment of predominant negative symptoms of patients with schizophrenia: A double-blind, active comparator-controlled trial

G. Németh<sup>1,\*</sup>, M. Debelle<sup>1</sup>, I. Laszlovszky<sup>1</sup>, E. Szalai<sup>1</sup>, B. Szatmári<sup>1</sup>, J. Harsányi<sup>1</sup>, Á. Barabássy<sup>1</sup>, S. Durgam<sup>2</sup>, I. Bitter<sup>3</sup>, S. Galderisi<sup>4</sup>

<sup>1</sup> Gedeon Richter Plc, medical division, Budapest, Hungary

<sup>2</sup> Forest research institute, clinical development, Jersey City, USA

<sup>3</sup> Semmelweis university, department of psychiatry and psychotherapy, Budapest, Hungary

<sup>4</sup> University of Naples SAN, psychiatry, Naples, Italy

\* Corresponding author.

**Objective** To examine the effect of cariprazine, a dopamine D<sub>3</sub>/D<sub>2</sub> receptor partial agonist with preferential binding to D<sub>3</sub> receptors, on predominant negative symptoms of schizophrenia.

**Methods** Subjects with schizophrenia and PANSS factor score for negative symptoms (PANSS-FSNS)  $\geq 24$  and no pseudospecific factors (e.g. extrapyramidal symptoms, depression) were randomized to cariprazine 4.5 mg/d (dose range: 3–6 mg/d) or risperidone 4 mg/d (dose range: 3–6 mg/d) for 6 months.

**Results** Four hundred and sixty-one patients were randomized 1:1 to double-blind risperidone ( $n = 231$ ) or cariprazine ( $n = 230$ ) treatment. Change from Baseline (CfB) at week 26 in the primary parameter, PANSS-FSNS, was larger in the cariprazine group than in the risperidone group (LSMD =  $-1.47$ ; 95% CI: [ $-2.39$ ,  $-0.53$ ];  $P = 0.002$ ) significant from week 14 onwards. CfB at week 26 in the functional parameter, Personal and Social Performance (PSP) total score, showed similarly greater improvement with cariprazine than risperidone (LSMD =  $4.63$ ; 95% CI: [ $2.71$ ,  $6.56$ ];  $P < 0.001$ ) significant from week 10 onward. Statistically significant differences in favor of cariprazine at week 26 were shown in the PSP areas of self-care, socially useful activities and personal and social relationships. Most patients tolerated the study treatment well, as reflected by low discontinuation rates due to adverse events (AEs). Adverse event profiles of cariprazine and risperidone were similar. The most common AEs during study treatment were insomnia (10.0%), and headache (10.4%), both in the risperidone group.

**Conclusion** 26-week cariprazine treatment, given as antipsychotic monotherapy, was significantly more effective on negative